Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kairos Pharma, Ltd. ( (KAPA) ) has provided an update.
On May 18, 2026, Kairos Pharma, Ltd. released a new investor presentation and made it available on its website while presenting it at the 2026 LD Micro Invitational XVI in Los Angeles, which ran from May 18 to 19, 2026. Chief Executive Officer John Yu used the presentation to update investors on the company’s clinical program and partnering activities, underscoring Kairos Pharma’s efforts to communicate its development trajectory and collaboration strategy to the market.
The most recent analyst rating on (KAPA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Kairos Pharma, Ltd. stock, see the KAPA Stock Forecast page.
More about Kairos Pharma, Ltd.
Kairos Pharma, Ltd. is a Delaware-incorporated biopharmaceutical company focused on developing clinical-stage therapies and advancing its drug pipeline through strategic partnerships. The company targets investors and industry stakeholders through capital markets events and specialized conferences to highlight progress in its clinical programs and collaboration efforts.
Average Trading Volume: 516,234
Technical Sentiment Signal: Sell
Current Market Cap: $10.32M
See more insights into KAPA stock on TipRanks’ Stock Analysis page.